# A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure

Study · id `cardio:ct-nct07584967` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07584967](<https://clinicaltrials.gov/study/NCT07584967>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07584967

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT07584967. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-15 (anticipated); primary completion 2028-07-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT07584967, source copy `cardio:ctgov-nct07584967-2026-11-12`, retrieved 2026-11-18)
- Planned start: 2026-11-15 (anticipated) (ClinicalTrials.gov record NCT07584967, source copy `cardio:ctgov-nct07584967-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2028-07-30 (anticipated) (ClinicalTrials.gov record NCT07584967, source copy `cardio:ctgov-nct07584967-2026-11-12`, retrieved 2026-11-18)
- Completion: 2028-08-30 (anticipated) (ClinicalTrials.gov record NCT07584967, source copy `cardio:ctgov-nct07584967-2026-11-12`, retrieved 2026-11-18)
- Countries: United States; Bulgaria; Canada; Czechia; Poland; Slovakia; Spain; Sweden (ClinicalTrials.gov record NCT07584967, source copy `cardio:ctgov-nct07584967-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07584967-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to Evaluate the Safety and Efficacy of AC01 Compared to Placebo in Participants With Chronic Heart Failure
- Acronym: GOAL-HF2
- Condition: Heart Failure With Reduced Ejection Fraction (HFrEF)
- Intervention (Drug): AC01
- Intervention (Other): Placebo
- Lead sponsor: AnaCardio AB
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition term reads as this condition, and the trial is coded with its broader condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)

## Provenance

Content hash: 02928d8c5498c52892116f6057fd24960501f3195657108eca0ab45ae1ea39fa
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
